Amryt Pharma Plc – Q1 2020 RESULTS

    NEXT STORY
    Myriad Receives FDA Approval of myChoice CDx® as Companion Diagnostic for Lynparza™ (olaparib) In Patients with Advanced Ovarian Cancer
    PREV STORY
    Paratek Pharmaceuticals Announces First Quarter 2020 Total Revenues of $7.9 Million including NUZYRA® (omadacycline) Net Sales of $7.3 Million
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Omega Commercial Finance Corporation Building Its Board & Management Team to Position Itself for the Long Term

    MIAMI, FL--(Marketwired - Aug 3, 2016) -  Omega Commercial Finance Corporation (OTCQB: OCFN), a ...

    author_avatar
    NASDAQ Market News

    Independent Data Monitoring Committee Recommends Discontinuation of the ADAPT Phase 3 Clinical Trial of Rocapuldencel-T in Metastatic Renal Cell Carcinoma for Futility Following Its Planned Interim Data Review

    -Company to host conference call today, February 22, 2017 at 8:30am EST- DURHAM, N.C., ...

    author_avatar
    NASDAQ Market News

    System Leaders Gather to Drive Improvement in Key Health Issues

    author_avatar
    NASDAQ Market News